Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 223

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 223
---
 portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, we intend 
 to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force.                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

| • |     | Leverage our management team’s experience to further develop and commercialize its current and future                                                                                                                                                  
 product portfolio. Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd. (“Teva”), Novartis Pharmaceuticals,              
 Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully 
 commercializing products.                                                                                                                                                                                                                              |

We believe that our innovative non-opioidproduct portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives. Our Management Team We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in the pharmaceutical industry, as well as strong transactional and business development track records. Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 60 years of global biopharmaceutical and biotechnology experience. Jaisim Shah has over 30 years of industry success in leading product development and commercializing innovative therapies and creating companies, with documented success in development and commercialization of some of today’s most recognized pharmaceutical brands. He is a seasoned life science executive and board director with extensive accomplishments at Scilex, Bristol-Myers Squibb, Roche, PDL Biopharma, Pfizer, and start-upssuch as Elevation. Mr. Shah has served as our Chief Executive Officer and President and as a member of our board of directors since the closing of the business combination in November 2022. He has also served as Chief Executive Officer and President of Legacy Scilex and Scilex Pharma since March 2019 and as a member of the board of directors of Scilex Pharmaceuticals, Inc., our wholly owned subsidiary (“Scilex Pharma”), since November 2016. Mr. Shah has served as Chief Executive Officer and President of Semnur Pharmaceuticals since its